Related Experiment Video
Updated: Jun 16, 2025
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors
Andrew Goetz1,2, Frances Shanahan3, Logan Brooks4
1gRED Computational Sciences, Genentech, South San Francisco, CA, US.
Purpose:
This study explores the potential of preclinical in vitro cell line response data and computational modeling in identifying optimal dosage requirements of pan-RAF (Belvarafenib) and MEK (Cobimetinib) inhibitors in melanoma treatment. Our research is motivated by the critical role of drug combinations in enhancing anti-cancer responses and the need to close the knowledge gap around selecting effective dosing strategies to maximize their potential.
Results:
In a drug combination screen of 43 melanoma cell lines, we identified unique dosage landscapes of panRAF and MEK inhibitors for NRAS vs BRAF mutant melanomas. Both experienced benefits, but with a notably more synergistic and narrow dosage range for NRAS mutant melanoma. Computational modeling and molecular experiments attributed the difference to a mechanism of adaptive resistance by negative feedback. We validated in vivo translatability of in vitro dose-response maps by accurately predicting tumor growth in xenografts. Then, we analyzed pharmacokinetic and tumor growth data from Phase 1 clinical trials of Belvarafenib with Cobimetinib to show that the synergy requirement imposes stricter precision dose constraints in NRAS mutant melanoma patients.
Conclusion:
Leveraging pre-clinical data and computational modeling, our approach proposes dosage strategies that can optimize synergy in drug combinations, while also bringing forth the real-world challenges of staying within a precise dose range.
Insights
Optimizing melanoma treatment with pan-RAF (Belvarafenib) and MEK (Cobimetinib) inhibitors requires precise dosing. This study reveals distinct dosage needs for NRAS vs BRAF mutant melanomas, crucial for effective combination therapy.
Area of Science:
- Oncology
- Pharmacology
- Computational Biology
Background:
- Drug combinations are vital for enhancing anti-cancer efficacy in melanoma.
- Optimal dosing strategies for combination therapies remain a knowledge gap.
- Pan-RAF (Belvarafenib) and MEK (Cobimetinib) inhibitors show promise in melanoma treatment.
Purpose of the Study:
- To identify optimal dosage requirements for pan-RAF (Belvarafenib) and MEK (Cobimetinib) inhibitors in melanoma using preclinical data and computational modeling.
- To explore the role of drug combinations in maximizing anti-cancer responses.
- To address the need for effective dosing strategies in melanoma treatment.
Main Methods:
- Conducted a drug combination screen of 43 melanoma cell lines.
- Utilized computational modeling and molecular experiments to analyze dose-response data.
- Validated in vitro findings with in vivo xenograft models and Phase 1 clinical trial data.
Main Results:
- Identified unique dosage landscapes for pan-RAF and MEK inhibitors in NRAS vs BRAF mutant melanomas.
- Observed more synergistic and narrower dosage ranges in NRAS mutant melanomas, linked to adaptive resistance mechanisms.
- Demonstrated in vitro-in vivo translatability of dose-response maps.
- Clinical data indicated stricter precision dose constraints for NRAS mutant melanoma patients.
Conclusions:
- Preclinical data and computational modeling can inform dosage strategies for optimizing drug combination synergy.
- Achieving optimal synergy requires adherence to precise dose ranges, presenting real-world challenges.
- Findings highlight the differential dosing requirements for NRAS and BRAF mutant melanomas.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...